Clinical trial
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
NCT00879086
Study timeline
Study start (actual)2009-03-31Date precision: day
Registry last updated2023-06-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
Eribulin MesylateDRUG · verified · RxNorm: eribulin mesylate
IxabepiloneDRUG · verified · RxNorm: ixabepilone
Sponsors & collaborators
Eisai Inc.lead sponsor
Mapped research locations
DallasTexas, United States3New YorkNew York, United States2HoustonTexas, United States2PortlandOregon, United States2VancouverWashington, United States2ChicagoIllinois, United States1Los AngelesCalifornia, United States1IndianapolisIndiana, United States1DetroitMichigan, United States1AustinTexas, United States1The BronxNew York, United States1New OrleansLouisiana, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00879086 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.